StockNews.AISignal intelligence
Company intelligence

CRVO

CervoMed Inc. · NASDAQ · Healthcare

Price$1.46+9.77% · +$0.13
Market cap22.09MEquity value
P / E-0.5Trailing ratio
Volume1.19MLatest session
Market data

CRVO price chart

TradingView
Related signals
1 min delayed

Browse public CRVO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CRVOOct 12, 2026-11.33% since signal

CervoMed reports nfPPA biomarker decline in Phase 2a; CRVO shares slump

CervoMed reported early Phase 2a nfPPA data showing a notable NfL decline from its open-label period, while GFAP remained unchanged and safety was generally favorable. The 12-week results come from 25 participants, with larger reductions in NfL among those starting with higher levels. The catalyst hinges on stronger clinical readouts and regulatory milestones beyond this biomarker signal.

View signal analysis
CRVOOct 8, 2025-8.27% since signal

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

CervoMed released Phase 2b trial results for neflamapimod. NFMD/B showed significant improvement in dementia severity compared to NFMD/A. Drug reduced risk of clinically meaningful progression by 75% versus placebo. Plasma GFAP changes correlated with dementia severity improvements. CervoMed shares rose 7.97%, trading above 200-day moving average.

View signal analysis
CRVOJul 28, 2025-12.75% since signal

CervoMed's Dementia Data Show Slowed Disease Progression

CervoMed reports positive 32-week data for neflamapimod in DLB patients. New capsules show statistically significant benefits over older batches. Subgroups with lower plasma ptau181 levels experienced greater risk reductions. Significant GFAP level reductions noted at week 32 for new capsule patients. CRVO stock up 29.4% following the announcement.

View signal analysis
CRVODec 10, 2024-11.41% since signal

CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MarketWatch

CervoMed's DLB treatment trial failed to meet primary goals, leading to a 77% drop. No approved treatments for DLB exist, affecting about 700,000 in the U.S. The drug neflamapimod did not achieve target plasma concentrations during trials. CervoMed pauses Phase 3 trial preparation, causing uncertainty about drug efficacy. Analyst downgrade to hold reflects concerns over trial execution and drug potential.

View signal analysis
Research

Company intelligence